| Literature DB >> 25792774 |
Abstract
Asymmetric catalysis is a powerful component of modern synthetic organic chemistry. To further broaden the scope and utility of asymmetric catalysis, new basic concepts for the design of asymmetric catalysts are crucial. Because most chemical reactions involve bond-formation between two substrates or moieties, high enantioselectivity and catalyst activity should be realized if an asymmetric catalyst can activate two reacting substrates simultaneously at defined positions. Thus, we proposed the concept of bifunctional asymmetric catalysis, which led us to the design of new asymmetric catalysts containing two functionalities (e.g. a Lewis acid and a Brønsted base or a Lewis acid and a Lewis base). These catalysts demonstrated broad reaction applicability with excellent substrate generality. Using our catalytic asymmetric reactions as keys steps, efficient total syntheses of pharmaceuticals and their biologically active lead natural products were achieved.Entities:
Keywords: Asymmetric catalyst; Brønsted base; Lewis acid; Lewis base; bifunctional; pharmaceutical synthesis
Year: 2006 PMID: 25792774 PMCID: PMC4323051 DOI: 10.2183/pjab.82.72
Source DB: PubMed Journal: Proc Jpn Acad Ser B Phys Biol Sci ISSN: 0386-2208 Impact factor: 3.493
Fig. 1.Structure of RELi3tris(binaphthoxide) heterobimetallic complexes (REMB).
Scheme 1.Preparation methods of rare earth-alkali metal heterobimetallic complexes from various rare earth metal sources.
Fig. 2.d-Glucose derived ligands and proposed transition state for catalytic enantioselective cyanosilylation of ketones.
Catalytic enantioselective cyanosilylation of ketones
| entry | ketone | metal source | ligand | loading (x mol %) | temp (°C) | time (h) | yield (%) | ee (%) |
|---|---|---|---|---|---|---|---|---|
| 1 |
| Gd(O | 1 | −40 | 16 | 93 | 91 | |
| 2 | Ti(O | 1 | −20 | 88 | 92 | 94 | ||
| 3 | Gd(O | 5 | −60 | 55 | 89 | 89 | ||
| 4 | Ti(O | 1 | −25 | 92 | 72 | 90 | ||
| 5 |
| Gd(O | 5 | −60 | 14 | 93 | 97 | |
| 6 | Ti(O | 1 | −10 | 92 | 90 | 92 | ||
| 7 |
| Gd(O | 5 | −60 | 6.5 | 94 | 87 | |
| 8 | Ti(O | 10 | −50 | 88 | 72 | 91 | ||
| 9 |
| Gd(O | 5 | −60 | 19 | 96 | 76 | |
| 10 | Ti(O | 2.5 | −30 | 92 | 72 | 90 | ||
| 11 |
| Gd(O | 5 | −60 | 1 | 97 | 66 | |
| 12 | Ti(O | 10 | −50 | 36 | 92 | 85 | ||
| 13 |
| Gd(O | 5 | −60 | 0.5 | 79 | 47 | |
| 14 | Ti(O | 2.5 | −45 | 92 | 80 | 82 |
Scheme 2.Catalytic asymmetric synthesis of key intermediates of pharmaceuticals.
Catalytic enantioselective Strecker reaction of ketoimines
| entry | substrate | conditions (x = loading) | time (h) | yield (%) | ee (%) |
|---|---|---|---|---|---|
| 1 |
| A (1) | 30 | 94 | 92 |
| 2 | B (0.1) | 19 | 97 | 90 | |
| 3 |
| A (1) | 31 | 97 | 95 |
| 4 |
| A (1) | 21 | 93 | 93 |
| 5 | B (1) | 3 | 99 | 99 | |
| 6 |
| A (1) | 22 | 92 | 92 |
| 7 |
| A (1) | 43 | 73 | 90 |
| 8 |
| A (2.5) | 2.5 | 91 | 80 |
| 9 |
| A (1) | 38 | 93 | 96 |
Conditions A = TMSCN (1.5 equiv) + 2,6-dimethylphenol (1 equiv). Conditions B = TMSCN (2.5∼5 mol %) + HCN (150 mol %).
Catalytic enantioselective conjugate addition of cyanide
| entry | substrate | catalyst (x mol %) | time (h) | yield (%) | ee (%) |
|---|---|---|---|---|---|
| 1 |
| 10 | 98 | 90 | 91 |
| 2 | 10 | 98 | 85 | 90 | |
| 3 |
| 5 | 42 | 91 | 98 |
| 4 |
| 5 | 42 | 89 | 97 |
| 5 |
| 5 | 88 | 87 | 90 |
| 6 |
| 20 | 139 | 78 | 93 |
| 7 |
| 5 | 8 | 99 (1.1/1) | 88/83 |
|
| |||||
|
|
| ||||
1 equiv of TMSCN was used.
0.5 equiv of TMSCN was used.
The reaction was performed at room temperature.
Diastereomer ratio.
Catalytic enantioselective ring-opening o f aziridines with TMSCN
| entry | substrate (R2 = | temp (°C) | time (h) | yield (%) | ee (%) |
|---|---|---|---|---|---|
| 1 |
| 0 | 20 | 94 (79) | 87 (>99) |
| 2 |
| r.t. | 69 | 81 | 93 |
| 3 |
| 60 | 64 | 92 (58) | 80 (>99) |
| 4 |
| r.t. | 95 | 85 (66) | 82 (>99) |
| 5 |
| r.t. | 42 | 91 | 83 |
| 6 |
| 60 | 96 | 92 | 88 |
| 7 |
| 60 | 23 | 89 | 84 |
| 8 |
| r.t. | 39 | 93 | 85 |
| 9 |
| r.t. | 96 | 44/37 | 90/89 |
After recrystallization. Recrystallization yield and its ee are shown in parentheses.
With 20 mol % Gd(O-i-Pr)3 and 40 mol % 5.
2.5 mol % TFA was used.
CH3CH2CN/CH2Cl2 = 1/2 was used as solvent.
Scheme 4.Conversion to cyclic β -Amino acid.